Clinically Validated Probiotics
Maximising Patient Engagement in Clinical Trials
The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding
Long-acting Injectable Formulations
LYMPHOMA TREATMENT AT A CROSSROADS
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Designing and Developing Green Drug Delivery Systems
Scientist, University of Kansas
Dr Sagar Salave is a Scientist at the University of Kansas USA specializing in mRNALNP therapeutics and viral vaccine formulation With a background in major pharmaceutical MNCs including Lupin and Ciron Drugs he possesses extensive expertise in drug discovery and nanotechnologydriven RD He serves as an Associate Editor for Applied Biochemistry and Biotechnology Journal Springer and sits on the Ed...
Articles
Government Investment in AI Capabilities will Cement Singapore’s Position as a Premier Clinical Trial Location
As Asia establishes itself as the global hub for clinical trials Singapore is bolstering its position as the preferred location for these trials to take place The countrys strong RD capabilities talent pool world class healthcare infrastructure and robust regulatory
Research Insights
Novel Insights into Post-myocardial Infarction Cardiac Remodeling Through Algorithmic Detection of Cell-type Composition Shifts
Interpreting bulk RNA sequencing from heterogeneous tissues like the postmyocardial infarction MI heart is confounded by dynamic changes in celltype composition To address this we developed a computational approach
Case Studies
Rapid, Comprehensive, And Aff Ordable Mycobacterial Diagnosis With Whole-genome Sequencing: A Prospective Case Study
Abstract Background Slow and cumbersome laboratory diagnostics for Mycobacterium tuberculosis complex MTBC risk delayed treatment and poor patient outcomes Wholegenome sequencing WGS could potentially provide a rapid and comprehensive diagnostic solution In this prospective study we compare realtime
Techno Trends
Spruce Biosciences Introduces Breakthrough TA-ERT for the Treatment of Sanfilippo Syndrome Type B
Spruce Biosciences has introduced Tralesinidase Alfa Enzyme Replacement Therapy TAERT as an investigational therapy that has received FDA Breakthrough Therapy Designation for the treatment of Sanfilippo Syndrome Type B MPS IIIB
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Machine Learning for New Drugs
Sneha Rai completed her Ph.D. from Computational and Structural Biology Lab., Department of Biological Sciences and Engineering at Netaji Subhas Institute of Technology (DU). She did masters in Bioinformatics from Banaras Hindu University and holds six years of bioinformatics research experience. Her area of interest includes structural bioinformatics, systems biology, protein/gene network analysis, data mining, computer aided drug designing, computational genomics, NGS data analysis, variant analysis and their clinical interpretation.
Venugopal Bhatia graduated from NSIT in 2019 with a B.E. in Biotechnology. During his undergraduate studies he was involved as an undergraduate researcher at the Computational and Structural Biology Laboratory and worked on two projects which were later published in Nature Scientific Reports and Elsevier Computational Biology and Chemistry. After a brief stint in industry, he's now pursuing his Master's at Yale.
Sonika Bhatnagar, Ph.D. (Biophysics), AIIMS works in the broad area of computational molecular biology. Her laboratory uses techniques of drug target selection, drug design & discovery, machine learning, and integrative genomics & proteomics towards Cardiovascular disease drug design and infectious disease therapeutics.
Chemistry & AI
Dr. Ashok Kumar FRSC, President of the Centre for Research & Development at Ipca, earned his PhD from CDRI with Dr. Nityanand and post-doctoral experience from Sussex University with Nobel Laureate Prof. Cornforth. His interests include Chemical, Biotechnological & NDDR research and also integrating spirituality, philosophy, and common sense in his professional and personal life.
Meet scientist Daria Donati
Daria’s work is ongoing. Her role at Cytiva involves identifying new and innovative technologies that can help in the development of therapeutics. This means building partnerships, improving manufacturing processes and, ultimately, getting life- saving drugs to the people who need them most.
Moving from Code to Consequence
Dr. Sanjesh Kumar is an Assistant Professor at Chandigarh University Uttar Pradesh with a Ph.D. in Pharmacology. An award-winning academician specialized in neurodegenerative disorders and advanced drug delivery, he has authored over 45 high-impact publications and holds multiple patents, seamlessly bridging the gap between clinical research and classroom education.
Dr. Disha Marwaha earned a Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI) in 2024 and currently serves as an Assistant Professor at Chandigarh University Uttar Pradesh. Her research encompasses nanomedicine, pharmacokinetics, formulation development, and targeted drug delivery systems. She has authored more than 22 articles in peer-reviewed international journals.
Why tier-2 and tier-3 cities are not included for clinical research
Co-Founder at DPHS Pvt. Ltd., Dr. Krutikesh Age is a researcher and a visionary committed towards propelling the field of clinical research and healthcare expansion in India. As the Co-founder of DPHS, Krutikesh manages varied key roles including Leadership, developing business and marketing strategies and Networking to name a few. It is through the deep understanding of clinical research and market dynamics that he has been instrumental in expanding the operations of DPHS in the past few years.
press releasesRead more...
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes high quality medicines for the treatment of cancer metabolic autoimmune and other major diseases today announced that a New Indication Application for sintilimab in combination with Nolgileuce...
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
The Menarini Group Menarini a leading international pharmaceutical and diagnostics company and Stemline Therapeutics Inc Stemline a whollyowned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients along with Georgiamune Inc a clinicalstage biot...
Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug
Aptar Pharma a global leader in drug delivery dosing protection technologies and services today announced the strategic acquisition of PULMOTREE a Munich Germanybased life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs The acquisition is expected t...
Kos Biotechnology Partners Announces Strategic Investment in Golden Age Health to Accelerate Global Access to Rare Disease Therapies
Kos Biotechnology Partners Kos a global life sciences investment firm bridging the US and European biopharma ecosystems today announced a strategic investment in Golden Age Health GAH through its inaugural fund Kos BioVentures As part of this partnership Alex Tzoukas Managing Partner and CoFounder
AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million
AI Proteins Inc a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC an affiliate of Astellas Pharma Inc TSE to discove...
Merck Collaborates with NVIDIA, Microsoft and Dawn Health to Develop Novel Support Model for People Living with Rare Tumors
Merck a leading science and technology company today announced a collaboration with NVIDIA Corporation Santa Clara California USA Microsoft Corporation Redmond Washington USA and Dawn Health AS Copenhagen Denmark to build an innovative model for Patient Support Programs PSPs The fourway collaboratio...
EventsRead more...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
LATEST NEWSRead more...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer
Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...
Okomera Signs Agreement with Servier for Cancer Research Technology
Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...
AstraZeneca and Oracle Launch Global AI Collaboration to Optimise Clinical Trials
AstraZeneca and Oracle Health and Life Sciences have launched a global collaboration to use artificial intelligence AI realworld data and cloud technology to improve clinical trial efficiency and patient outcomes The collaboration will combine AstraZenecas expertise in drug development clinical rese...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
